PEOPLE ON THE MOVE
PlasmaTech
The board of PlasmaTech Biopharmaceuticals has appointed Todd Wider as a director. The biotech develops gene therapies for rare diseases.
Wider has spent his career at small and mid-level biotech companies, and is experienced in public and private financings, corporate development and licensing transactions. He holds a medical degree from Columbia College of Physicians and Surgeons
"We are extremely pleased to be able to add Todd to our board of directors," said executive chairman Steven Rouhandeh. "Todd brings to the board a unique blend of skills and experience that will be of great value to the Company as we continue to build out our product pipeline in cell and gene therapies focused on rare diseases."
Earlier this month, PlasmaTech acquired startup Abeona Therapeutics. As a result, the company announced it is developing a large molecule therapy for Sanfilippo Syndrome. It is also pursuing two platforms, Salt Diafiltration Process and Polymer Hydrogel Technology.
